Presentation is loading. Please wait.

Presentation is loading. Please wait.

NewPath Molecular Research

Similar presentations

Presentation on theme: "NewPath Molecular Research"— Presentation transcript:

1 NewPath Molecular Research
Investor Overview Biotech and Money Feb 2015 Dr Elizabeth Farrant

2 Contract Discovery Research
The Market Opportunity Market Evolution Outsourcing of discovery services is a growing global market Predicted to grow to $21Bn by 2016 $4.5Bn of this is predicted to be chemical synthesis In recent years, outsourcing has been driven by pressures to improve the productivity of R&D spend Reduced internal R&D capability Requirement for fungible contract resource on projects Increased outsourcing to lower cost economies However, increasingly, wage inflation (lower cost economies)and competition (higher cost economies) is reducing the differential Outsourcing decisions are increasingly made on the basis of competency rather than cost Biomarket Trends 2012 Vol 32 No 11

3 The Innovation Gap in Pharma
Pharma has seen: Reduced numbers of innovative products Increasing costs to market for products Shorter exclusivity due to “me too” products The “low hanging fruit” drug targets have been addressed New targets are difficult to address with current approaches Dr Youssef Bennani, Vertex: A consequence of outsourcing has been to reduce chemical innovation in small molecule research There is unfulfilled demand in pharma and biotech for innovative chemical matter Y. L. Bennani, Drug Discovery Today, 2011, Vol 16, p 779

4 NewPath Molecular The 21st century chemistry lab Client Example
NewPath is commercialising the research of Prof S Ley (Cambridge University) Using modular machine assisted chemistry to make the right molecules, not the easy molecules Client 1 have discovered a complex molecule with promise in a key unmet medical need Production using current technologies is not commercially viable NewPath are developing an innovative, commercially viable, route to the molecule to enable innovation in a key unmet medical need

5 The Founders Prof Steve V. Ley CBE FRS FMedSci Dr Nikzad Nikbin (CTO)
Involved in 3 spin-out companies Consultant to 6 major pharmaceutical companies Dr Nikzad Nikbin (CTO) 8 years developing machine assisted synthesis techniques in the University of Cambridge Innovative Technology Centre Dr Elizabeth Farrant FRSC (CEO) 17 years experience in Pharma and contract research medicinal chemistry services Andrew MacCormack 17 years at JP Morgan Active investor in numerous start-ups, most notably Intervate Limited, a renewable energy company

6 The Business Model Fee for Service revenue model FTE rate based
PROFIT & LOSS STATEMENT FY2015 FY2016 FY2017 FY2018 FY2019 Revenues CRO Revenues 292,500 390,133 1,446,667 3,402,000 3,724,000 Grant Revenues 16,846 18,841 15,400 12,587 10,288 Total Revenues 309,346 408,974 1,462,066 3,414,587 3,734,288 Direct Costs Consumables 9,000 13,200 48,000 Licensing / Royalty 8,775 11,704 43,400 102,060 111,720 Software 18,000 24,000 36,000 72,000 Equipment Operations & Maintenance 9,600 30,720 45,120 64,320 88,320 R&D Expense R&D Out-sourcing 10,500 21,000 3,000 6,000 58,875 106,624 178,520 268,380 326,040 Personnel 194,985 255,905 998,267 1,506,505 1,544,168 Gross Operating Profit / (Loss) 55,486 46,445 285,279 1,639,702 1,864,080 Overheads Facilities 5,100 75,000 105,000 150,000 180,000 Insurance 5,040 6,135 29,241 68,292 74,686 Professional Fees 1,200 21,931 51,219 56,014 IP 2,040 12,000 Business Development 7,200 Training, Periodicals, Publications 1,380 1,800 2,100 Bank Charges 600 21,960 100,709 194,872 309,711 350,900 EBITDA 33,526 (54,264) 90,407 1,329,991 1,513,180 Fee for Service revenue model FTE rate based Already secured contract to cover first 15 months operating costs Seeking £500k seed funding to: accelerate the development and IP protect the machine assisted chemistry lab Scale the business in year 3

7 For more information: Elizabeth Farrant
+44 (0)

Download ppt "NewPath Molecular Research"

Similar presentations

Ads by Google